Adebrelimab plus chemo before surgery for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy before surgery for pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have pancreatic cancer that has been confirmed by a biopsy and can be surgically removed, with a CA19-9 level above 150.
- You have not had any previous chemotherapy or other systemic treatment for your pancreatic cancer.
- Your tumor is measurable on a CT scan (at least 1 cm).
- You are in fairly good health (ECOG score 0 or 1) and your blood counts, liver, and kidney function are within certain ranges.
- You have not had prior treatment with a PD-1 or PD-L1 inhibitor (a type of immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This trial tests a combination of two drugs (HRS-4642 and adebrelimab) for people with advanced pancreatic cancer that has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests combining a targeted drug (nimotuzumab) with two chemotherapy drugs (nab-paclitaxel and gemcitabine) before and after surgery for pancreatic cancer that can be surgically removed but has high-risk features or is borderline resectable. The goal is to see if this approach improves outcomes.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.